IGC Pharma, Inc. (NASDAQ:IGC) | WebDisclosure

Basculer en Français

10162	Companies
208766	Keywords
138869	Articles
110653	Press releases

Home
Companies
IGC Pharma, Inc.

PRESS RELEASE

published on 11/14/2024 at 14:30, 1 year 4 months ago

IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer’s Pipeline
IGC Pharma, Inc. announces Q2 FY2025 financial results and strategic advancements including breakthroughs in Alzheimer's treatment pipeline. Revenue grows 42% to $412k. R&D expenses decrease 28%

Financial Results R&D Expenses Q2 FY2025 IGC Pharma Alzheimer's Treatment
BRIEF

published on 11/06/2024 at 14:35, 1 year 4 months ago

IGC Pharma met en avant des avancées stratégiques dans les thérapies contre la maladie d'Alzheimer et la perte de poids

Intelligence Artificielle Perte De Poids Agonistes Du GLP-1 IGC Pharma Traitement De La Maladie D'Alzheimer
BRIEF

published on 11/06/2024 at 14:35, 1 year 4 months ago

IGC Pharma Highlights Strategic Advances in Alzheimer's and Weight Loss Therapies

Weight Loss Artificial Intelligence GLP-1 Agonists IGC Pharma Alzheimer's Treatment
PRESS RELEASE

published on 11/06/2024 at 14:30, 1 year 4 months ago

IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer’s and Weight Loss Therapies
IGC Pharma, Inc. (NYSE American: IGC) announces a new interview with CEO Ram Mukunda discussing strategic expansion into metabolic and neurological markets, focusing on Alzheimer's and weight loss therapies, leveraging AI for diverse pipeline

Interview Neurodegenerative Disorders Metabolic Disorders IGC Pharma Ram Mukunda
BRIEF

published on 10/17/2024 at 14:35, 1 year 5 months ago

IGC Pharma étend son essai sur la maladie d'Alzheimer au Canada grâce à un partenariat avec Baycrest

IGC Pharma IGC-AD1 Essai Sur La Maladie D'Alzheimer Partenariat Baycrest Phase 2 Clinique
BRIEF

published on 10/17/2024 at 14:35, 1 year 5 months ago

IGC Pharma Expands Alzheimer's Trial to Canada with Baycrest Partnership

IGC Pharma Alzheimer's Trial IGC-AD1 Baycrest Partnership Phase 2 Clinical
PRESS RELEASE

published on 10/17/2024 at 14:30, 1 year 5 months ago

IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1
IGC Pharma expands Phase 2 trial to Canada at Baycrest Academy for Research and Education in Toronto, Ontario, to investigate IGC-AD1 for treating agitation in Alzheimer's dementia

Phase 2 Trial Alzheimer's IGC Pharma Agitation Treatment Baycrest Academy
BRIEF

published on 10/03/2024 at 15:05, 1 year 6 months ago

IGC Pharma Secures Two Awards in NIH's AI PREPARE Challenge

AI Technology Healthcare Innovation IGC Pharma Alzheimer's Prediction NIH Challenge
BRIEF

published on 10/03/2024 at 15:05, 1 year 6 months ago

IGC Pharma remporte deux prix lors du concours AI PREPARE Challenge du NIH

Technologie De L'IA Innovation Dans Le Domaine De La Santé IGC Pharma Prédiction De La Maladie D'Alzheimer Défi Du NIH
PRESS RELEASE

published on 10/03/2024 at 15:00, 1 year 6 months ago

IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge
IGC Pharma, Inc. wins 2 awards in the PREPARE Challenge for Alzheimer's research with its MHAS entry. Recognition highlights leadership in AI for disease prediction

Artificial Intelligence Healthcare Innovation Alzheimer's Research IGC Pharma PREPARE Challenge

Accesswire

Published on 04/06/2026 at 13:15, 18 minutes ago

Avino Announces Normal Course Issuer Bid for Common Shares
Published on 04/06/2026 at 13:00, 33 minutes ago

Revolve Signs Interconnection Agreement for 130 MW EL 24 Wind Project in Mexico
Published on 04/02/2026 at 22:00, 3 days 15 hours ago

Star Copper Announces Closing of Charity Flow-Through Unit Private Placement
Published on 04/02/2026 at 18:32, 3 days 19 hours ago

Datavault AI CEO Nathaniel Bradley to Present DataValue(R), DataScore(R), and Information Data Exchange(R) Technologies at XRP Tokyo 2026
Published on 04/02/2026 at 15:00, 3 days 22 hours ago

Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress

View all ACCESSWIRE

EQS Group

Published on 04/06/2026 at 12:20, 1 hour 13 minutes ago

DataBeyond Unveils Asia's Largest Unmanned AI Sorting Center, Setting a New Circular Economy Benchmark
Published on 04/06/2026 at 10:05, 3 hours 28 minutes ago

K-679: A Novel Antibody Drug-loaded Unimicelle Conjugate Demonstrates Tumor-Selective Pharmacokinetics, Extensive Intratumoral Distribution and Superior Efficacy in Non-Clinical Animal Models
Published on 04/06/2026 at 09:05, 4 hours 28 minutes ago

McDonald's Türkiye Launches Campaign Spotlighting Driving Safety
Published on 04/04/2026 at 10:07, 2 days 3 hours ago

Heidelberg Pharma to Present Data from its ADC Technology Platform at AACR Annual Meeting 2026
Published on 04/04/2026 at 02:05, 2 days 11 hours ago

Blokees made its debut at 2026 Thailand Toy Expo, exhibiting multiple products

Les Echos

Published on 04/03/2026 at 18:46, 2 days 18 hours ago

Disclosure of Share Capital and Voting Rights as of March 31, 2026
Published on 04/03/2026 at 18:46, 2 days 18 hours ago

Déclaration du nombre d’actions et droits de vote au 31 mars 2026
Published on 04/03/2026 at 18:01, 2 days 19 hours ago

ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 04/03/2026 at 18:00, 2 days 19 hours ago

ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 04/03/2026 at 18:00, 2 days 19 hours ago

LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 mars 2026

View all LES ECHOS COMFI WIRE